311 related articles for article (PubMed ID: 31744469)
21. Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
Zhou L; Lin J; Chen J; Zhang S
J Cancer Res Ther; 2021 Dec; 17(7):1730-1735. PubMed ID: 35381746
[TBL] [Abstract][Full Text] [Related]
22. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
Luo Y; Qin Y; Lang J
Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
[TBL] [Abstract][Full Text] [Related]
23. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Wu M; Ou D; He X; Hu C
Oral Oncol; 2017 Oct; 73():118-123. PubMed ID: 28939063
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
[TBL] [Abstract][Full Text] [Related]
26. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
27. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
[TBL] [Abstract][Full Text] [Related]
28. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
[TBL] [Abstract][Full Text] [Related]
29. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
30. Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression.
Mao L; Tan J; Wang F; Luo Y; Liu W; Zeng F; Yu B; Huang H; Lu J; Peng X; Liu X
Clin Otolaryngol; 2019 Jul; 44(4):572-580. PubMed ID: 30972891
[TBL] [Abstract][Full Text] [Related]
31. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial.
Tang QN; Liu LT; Qi B; Guo SS; Luo DH; Sun R; Sun XS; Chen DP; Guo L; Mo HY; Wang P; Liu SL; Liang YJ; Li XY; Yang ZC; Chen QY; Mai HQ; Tang LQ
JAMA Netw Open; 2021 Dec; 4(12):e2138470. PubMed ID: 34928359
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab in the treatment of nasopharyngeal carcinoma with cervical lymph node metastasis.
Lu J; Wei J; Xiao X; Wei Y; Li M; Huang Y; Deng W; Wang H; Gui Z; Liu F; Jiang H; Zhang J; Weng J; Qu S
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2479-2488. PubMed ID: 36577788
[TBL] [Abstract][Full Text] [Related]
33. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
[TBL] [Abstract][Full Text] [Related]
34. Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity-modulated radiotherapy.
Chang H; Peng L; Tao YL; Chen C; Xiao WW; Hu YH; Gao YH
Cancer Med; 2019 Jun; 8(6):2823-2831. PubMed ID: 31006996
[TBL] [Abstract][Full Text] [Related]
35. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
[TBL] [Abstract][Full Text] [Related]
36. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.
Chen Y; Sun Y; Liang SB; Zong JF; Li WF; Chen M; Chen L; Mao YP; Tang LL; Guo Y; Lin AH; Liu MZ; Ma J
Cancer; 2013 Jun; 119(12):2230-8. PubMed ID: 23576020
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma.
Fei Z; Xu T; Li M; Chen T; Li L; Qiu X; Chen C
Radiat Oncol; 2020 Oct; 15(1):230. PubMed ID: 33008416
[TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy with sequential nimotuzumab plus concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma: A retrospective real-world study.
Jiang D; Cao J; Guo L; Chen Y; Yuan G; Huang J
Medicine (Baltimore); 2023 Jan; 102(4):e32732. PubMed ID: 36705354
[TBL] [Abstract][Full Text] [Related]
39. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
Wang L; Wu Z; Xie D; Lv S; Xia L; Su Y
Radiat Oncol; 2020 Jul; 15(1):160. PubMed ID: 32615984
[TBL] [Abstract][Full Text] [Related]
40. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis.
Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
BMC Cancer; 2018 Mar; 18(1):323. PubMed ID: 29580204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
